|
Market Cap (4-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 11 April 2023, 12:17. The announcement is marked as price sensitive, and is 2 page(s) in length and 160.83kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.003% short sold according to ASIC data. It was ranked the 634th most shorted stock on the ASX. It is now ranked as the 629th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| Dose Escalation Approved in ACCENT Clinical Trial of AMP945 | 11 April 2023, 12:17 |
| ACCENT Trial Recruitment Progress | 28 February 2023, 11:29 |
| ATX - US Conference Presentation | 23 February 2023, 16:55 |
| AmpliaTherapeutics - Lorne Cancer Conference Presentation | 9 February 2023, 8:16 |
You must be logged in to post a reply.
Amplia Therapeutics 